FDA posted a proposed order on November 10 to move immunohistochemistry test systems used with an approved oncology therapeutic from class III to class II, subject to 510(k). The notice is scheduled to publish in the Federal Register on November 12 under docket FDA-2026-N-12508. Comments close 60 days after publication.

The order would create 21 CFR 864.1895 and amend the identification paragraph of 864.1860. Twelve product codes move with it: MVC, NKF, QQT, NQF, PLS, PKW, QUL, QNH, QZJ, SBL, SER and SHF. Proposed special controls cover analytical specificity, precision and reproducibility, robustness, linearity for quantitative results, specimen stability, cut-off criteria and clinical performance data. Labeling would have to carry a performance summary, a limiting statement on interpretation by qualified readers, and indication language consistent with the therapeutic product's own.

This is the third piece of the same program. FDA proposed down-classing nucleic acid based oncology companion tests in November 2025, then reclassified in situ hybridization test systems in August 2026. For a diagnostics startup the practical change is the submission type. A PMA becomes a 510(k) against published special controls, which takes years and several million dollars out of a companion diagnostic program.